A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study-Reference-Cited by-同舟云学术

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study

Published:2018-03-16 Issue:5 Volume:265 Page:1174-1183
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Lanzillo Roberta, ,Prosperini Luca^ORCID,Gasperini Claudio,Moccia Marcello,Fantozzi Roberta,Tortorella Carla,Nociti Viviana,Annovazzi Pietro,Cavalla Paola,Radaelli Marta,Malucchi Simona,Clerici Valentina Torri,Boffa Laura,Buttari Fabio,Ragonese Paolo,Maniscalco Giorgia Teresa,Di Filippo Massimiliano,Buscarinu Maria Chiara,Pinardi Federica,Gallo Antonio,Coghe Giancarlo,Pesci Ilaria,Laroni Alice,Gajofatto Alberto,Calabrese Massimiliano,Tomassini Valentina,Cocco Eleonora,Solaro Claudio

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00415-018-8831-x/fulltext.html

Reference25 articles.

1. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlledtrial. Neurology 43:655–661

2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504

3. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Multiple Sclerosis Collaborative Research Group (MSCRG): intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294

4. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276

5. O’Rourke KE, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler J 11:46–50

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Nanoparticles for Skin Protection — A Review;Nano LIFE;2024-08-09

2. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-10

3. Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review;International Journal of MS Care;2023-09-01

4. Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis;Toxins;2022-11-09

5. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy;Journal of Neurology;2022-08-11